Literature DB >> 17443427

[Retinal toxicity of intravitreal doxycycline. A pilot study].

E Aydin1, A A Kazi, G A Peyman, M R Esfahani, A Muñoz-Morales, M Kivilcim, M Caro-Magdaleno.   

Abstract

OBJECTIVE: To assess the retinal toxicity of varying concentrations of intravitreally administered doxycycline, a member of tetracycline family.
METHODS: Fourteen New Zealand albino rabbits, divided into 5 groups, were used for this study. The initial concentration of doxycycline (100 mg) was titrated using 5% dextrose solution to the following concentrations in a volume of 0.1 ml: 2000 microg, 1000 microg, 500 microg, 250 microg, 125 microg, and 62.5 microg. Each concentration was injected into 2 rabbit eyes. Two control eyes received 0.1 ml of 5% dextrose solution. All animals were examined before and after injection using indirect ophthalmoscopy and slit-lamp biomicroscopy. Electroretinography (ERG) was performed on all animals prior to the intravitreal injection and 2 weeks post-injection. The animals were re-examined at this time by indirect ophthalmoscopy and slit-lamp biomicroscopy and were then subjected to euthanasia. Their eyes were enucleated and examined using light microscopy.
RESULTS: The doxycycline injected group exhibited significant decreases in ERG of the eyes injected with 2000 microg, 1000 microg, 500 microg, and 250 microg/0.1 ml. No significant changes in the ERG were observed following the injection of lesser concentration levels. There were no signs of retinal toxicity on slit-lamp examination, indirect ophthalmoscopy, or light microscopy in all the eyes injected with doxycycline concentrations of 125 microg or lower.
CONCLUSIONS: Doxycycline injected intravitreally appeared safe at concentrations of 125 microg/0.1 ml or less in albino rabbits. Intravitreal doxycycline may be beneficial, and is an inexpensive alternative drug which could be used in the treatment of bacterial endophthalmitis particularly against resistant Staphylococcus aureus organisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443427     DOI: 10.4321/s0365-66912007000400007

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  3 in total

1.  Safety of intravitreal quinupristin/dalfopristin in an animal model.

Authors:  Veronica E Giordano; Sergio E Hernandez-Da Mota; Tania N Adabache-Guel; Armando Castillejos-Chevez; Sonia Corredor-Casas; Samantha M Salinas-Longoria; Rafael Romero-Vera; Juan M Jimenez-Sierra; Jose L Guerrero-Naranjo; Virgilio Morales-Canton
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

Review 2.  Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Authors:  Medikonda Radhika; Kopal Mithal; Abhishek Bawdekar; Vivek Dave; Animesh Jindal; Nidhi Relhan; Thomas Albini; Avinash Pathengay; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-09-10

Review 3.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.